Axsome Therapeutics Insider's Sequential Stock Sales Raise Investor Attention
Rhea-AI Filing Summary
Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144. The filing indicates planned sale of 7,500 shares of common stock with an aggregate market value of $768,503 through Charles Schwab & Co.
Key transaction details:
- Securities acquired through employee stock option exercise on June 20, 2025
- Payment made via broker payment for cashless exercise
- Total shares outstanding: 49,236,365
- Planned sale date: June 20, 2025
The filing also discloses previous sales by Hunter R. Murdock in the past 3 months totaling 22,500 shares across three transactions from June 16-18, 2025, with gross proceeds ranging from $751,975 to $768,154. The seller represents no knowledge of undisclosed material adverse information regarding the issuer.
Positive
- None.
Negative
- Insider Hunter R. Murdock has sold a total of 22,500 shares over three consecutive days (June 16-18, 2025) for approximately $2.28M, followed by another planned sale of 7,500 shares, indicating consistent selling pressure from management
FAQ
How many AXSM shares were sold by Hunter R. Murdock in June 2025?
What was the total value of AXSM shares sold by Hunter Murdock in mid-June 2025?
How did Hunter Murdock acquire the AXSM shares being sold?
What is the total number of outstanding AXSM shares according to the June 2025 Form 144?
Through which broker is Hunter Murdock selling AXSM shares?